Online inquiry

IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4461MR)

This product GTTS-WQ4461MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets SLAMF7 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001282588.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57823
UniProt ID Q9NQ25
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4461MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7692MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GEXMab73
GTTS-WQ15269MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ14837MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA SGN-75
GTTS-WQ1119MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-927
GTTS-WQ12904MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ15708MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA VIR-7831
GTTS-WQ9999MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA KRN-23
GTTS-WQ14390MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW